Citadel Advisors’s Akoya BioSciences AKYA Stock Holding History

Citadel Advisors’s Portfolio AKYA Stock Details AKYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,000	Closed	-$1.39K	–	12370
2025 Q1	$1.39K	Sell	1,000 -1,000	-50%	-$2.19K	﹤0.01%	14135
2024 Q4	$4.58K	Buy	+2,000	New	+$5.3K	﹤0.01%	13919
2024 Q1	–	Sell	-500	Closed	-$2.44K	–	14489
2023 Q4	$2.44K	Sell	500 -900	-64%	-$3.74K	﹤0.01%	13698
2023 Q3	$6.51K	Sell	1,400 -12,600	-90%	-$72.4K	﹤0.01%	13314
2023 Q2	$103K	Buy	14,000 +12,000	+600%	+$80.1K	﹤0.01%	10880
2023 Q1	$16.4K	Buy	2,000 +1,800	+900%	+$18.8K	﹤0.01%	13208
2022 Q4	$1.91K	Buy	+200	New	+$2.46K	﹤0.01%	14397
2022 Q2	–	Sell	-11,500	Closed	-$126K	–	12786
2022 Q1	$126K	Buy	+11,500	New	+$133K	﹤0.01%	12035

Citadel Advisors's AKYA Position: Q3 2025 in Review

Citadel Advisors sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 100,467 shares — an estimated $131K sold.

Citadel Advisors first reported a position in AKYA in Q2 2021 and held it in 14 quarters. The position peaked at $1.33M in Q4 2022. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.

Citadel Advisors reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 100,467 Akoya BioSciences shares in Q3 2025, an estimated $131K.
Citadel Advisors first reported a position in Akoya BioSciences in Q2 2021 and held it in 14 quarters.
Citadel Advisors's Akoya BioSciences position peaked at $1.33M in Q4 2022.
0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.